Susan Schneider becomes CMO at ThromboGenics

Company: ThromboGenics NV

Appointee: Susan Schneider



Susan Schneider, a former executive at Allergan Plc, has joined ThromboGenics NV as chief medical officer to oversee the development of the Belgian company’s pipeline targeting diabetic eye disease. At Allergan, she was therapeutic area head of retina and glaucoma. She received her medical degree from the Medical College of Pennsylvania, US.

Also joining the company as chief commercial officer is Vinciane Vangeersdaele, recently head of ophthalmology for Europe at Novartis AG. Ms Vangeersdaele will lead the commercial strategy for Jetrea (ocriplasmin) a drug for treating symptomatic vitreomacular adhesion. ThromboGeneics, which developed Jetrea, recently regained full rights to the drug from the licensee which was Novartis.

ThromboGenics announced the appointments on 8 November 2017.

 Copyright 2017 Evernow Publishing Ltd